Holen Sie sich die Stockscreener-App
20.43
1.40%
-0.29
Handel nachbörslich:
20.72
0.29
+1.42%
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - newser.com
How high can Arcutis Biotherapeutics Inc. stock go2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Can Arcutis Biotherapeutics Inc. hit a new high this monthQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
What the charts say about Arcutis Biotherapeutics Inc. today2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitQuarterly Performance Summary & Daily Chart Pattern Signals - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Should you wait for a breakout in Arcutis Biotherapeutics Inc.July 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growth2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Capital Efficiency Focused Ideas - newser.com
How to interpret RSI for Arcutis Biotherapeutics Inc. stockJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Sentiment analysis tools applied to Arcutis Biotherapeutics Inc.Market Growth Report & Daily Market Momentum Tracking - newser.com
Arcutis Biotherapeutics Hits New 52-Week High of $21.55 - Markets Mojo
Arcutis Biotherapeutics reaches milestone recognized by Nasdaq - Traders Union
Wealth Enhancement Advisory Services LLC Purchases Shares of 15,666 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Is Arcutis Biotherapeutics Inc. stock bottoming out2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year HighStill a Buy? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD - Investing.com
Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales - Investing.com
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - BioSpace
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $26 - 富途牛牛
FDA approves ZORYVE cream for atopic dermatitis in young children By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in Stock - MarketBeat
Arcutis Biotherapeutics Hits New 52-Week High of $21.30 - Markets Mojo
FDA Approves Roflumilast Cream 0.05% for Atopic Dermatitis in Children 2 to 5 - Drug Topics
Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children - Investing.com
ARQT: FDA Approves ZORYVE Cream for Young Children's Atopic Dermatitis - GuruFocus
FDA approves ZORYVE cream for atopic dermatitis in young children - Investing.com
Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5 - Quiver Quantitative
1.8M U.S. children ages 2–5 treated topically — Arcutis' ZORYVE 0.05% FDA‑approved, available Oct 2025 - Stock Titan
Fishman Jay A Ltd. MI Purchases 23,000 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What drives Arcutis Biotherapeutics Inc stock priceMarket Sentiment Extremes & Ride the Wave of Market-Beating Growth - earlytimes.in
Is Arcutis Biotherapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% Following Insider Selling - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% After Insider Selling - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 24,261 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 20,739 Shares - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule - MarketScreener
94,500 RSUs Granted — Arcutis Reports Inducement Grants to 12 New Hires, Vesting Over Four Years - Stock Titan
Will Arcutis Biotherapeutics Inc. stock split attract more investorsOptions Play & Weekly Chart Analysis and Guides - newser.com
Arcutis Biotherapeutics Achieves 101.39% Stock Surge, Establishing It as a Multibagger Performer - Markets Mojo
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):